[1] Shouval D, et al. ANTI-VIRAL EFFECTS, PHARMACOKINETICS AND SAFETY OF TWO HUMAN MONOCLONAL ANTI-HBS (LIBIVIRUMAB/EXBIVIRUMAB) VERSUS HEPATITIS B IMMUNE GLOBULIN (HBIG) IN HEPATITS B VIRUS (HBV) IN LIVER TRANSPLANT (LT) RECIPIENTS: 22[J]. Hepatology, 2006, 44: 196A.